TW202227046A - 三苯基鈣敏感性化合物之治療方法 - Google Patents

三苯基鈣敏感性化合物之治療方法 Download PDF

Info

Publication number
TW202227046A
TW202227046A TW110134985A TW110134985A TW202227046A TW 202227046 A TW202227046 A TW 202227046A TW 110134985 A TW110134985 A TW 110134985A TW 110134985 A TW110134985 A TW 110134985A TW 202227046 A TW202227046 A TW 202227046A
Authority
TW
Taiwan
Prior art keywords
cltx
dose
cca
blood
dosing regimen
Prior art date
Application number
TW110134985A
Other languages
English (en)
Chinese (zh)
Inventor
塞門 布魯斯
強納森 法克斯
格羅索 拉梅 薩尼
阿里 柯梅力
阿南特 斯里達
馬利 史考特 羅伯茨
Original Assignee
美商柯西立提克斯療法有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商柯西立提克斯療法有限公司 filed Critical 美商柯西立提克斯療法有限公司
Publication of TW202227046A publication Critical patent/TW202227046A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110134985A 2020-09-18 2021-09-17 三苯基鈣敏感性化合物之治療方法 TW202227046A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US63/080,165 2020-09-18
US202163159397P 2021-03-10 2021-03-10
US63/159,397 2021-03-10

Publications (1)

Publication Number Publication Date
TW202227046A true TW202227046A (zh) 2022-07-16

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110134985A TW202227046A (zh) 2020-09-18 2021-09-17 三苯基鈣敏感性化合物之治療方法

Country Status (10)

Country Link
US (1) US20220087961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542932A (cg-RX-API-DMAC7.html)
KR (1) KR20230112609A (cg-RX-API-DMAC7.html)
AU (1) AU2021343475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192684A1 (cg-RX-API-DMAC7.html)
IL (1) IL301409A (cg-RX-API-DMAC7.html)
MX (1) MX2023003129A (cg-RX-API-DMAC7.html)
TW (1) TW202227046A (cg-RX-API-DMAC7.html)
WO (1) WO2022060987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2024220796A1 (en) * 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂

Also Published As

Publication number Publication date
EP4213829A1 (en) 2023-07-26
WO2022060987A1 (en) 2022-03-24
IL301409A (en) 2023-05-01
MX2023003129A (es) 2023-08-04
US20220087961A1 (en) 2022-03-24
AU2021343475A1 (en) 2023-06-01
KR20230112609A (ko) 2023-07-27
AU2021343475A9 (en) 2024-05-02
CA3192684A1 (en) 2022-03-24
JP2023542932A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
US20220323445A1 (en) Reducing immunogenicity to pegloticase
US12465631B2 (en) Reducing immunogenicity to pegloticase
PT2275086E (pt) Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
KR100445946B1 (ko) 폐고혈압 치료법
KR102472588B1 (ko) 니트라이트의 약제학적 제형 및 이의 용도
JP2020522571A (ja) 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画
US20220409620A1 (en) Reducing immunogenicity to pegloticase
US20220087961A1 (en) Treatment methods of triphenyl calcilytic compounds
JP2002518323A (ja) 選択的エストロゲン受容体修飾物質と上皮小体ホルモンとを含む治療用組合わせ物
TWI590829B (zh) 口服b12的療法
JPH11507012A (ja) 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
JP2002518326A (ja) 筋骨格脆性治療のための(選択的)エストロゲンレセプターモジュレーター(serm)及び成長ホルモン分泌促進剤(ghs)の治療用組合せ
TW202506101A (zh) 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療
ES2264444T3 (es) Composicion farmaceutica que comprende furosemida y conivaptan para el tratamiento de insuficiencia cardiaca congestiva.
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
US20210085711A1 (en) Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
WO2026078027A1 (en) Dosage regimens for camlipixant in treating chronic cough
WO2026032924A1 (en) Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough
JP2003521496A (ja) Ace阻害剤−バソプレッシンアンタゴニストの組み合わせ
Pawlukiewicz et al. Proton pump inhibitor-induced hypomagnesemia: a rare, potentially fatal complication
US20220305021A1 (en) Methods of treating and/or preventing psoriasis
JP2018039748A (ja) 変異を有するi型コラーゲンの小胞体内過剰蓄積正常化剤
Salusky et al. Recent advances in the management of renal osteodystrophy in children